Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
CHUYÊN ĐỀ Issue: Số 75+76 (2018)

No translate

Published: November 16, 2026
Views: 562

Abstract

No translate

Keywords
No translate

References

1.
1. Connolly SJ, Ezekowitz MD, Yusuf S, et al, and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
2.
2. Patel MR, Mahaffey KW, Garg J, et al, and the ROCKET AF Steering Committee, for the ROCKET AF Investigators. RivaroXaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883- 891.
3.
3. Granger CB, Alexander JH, McMurray JJV, et al, for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
4.
4. Giugliano RP, Ruff CT, Braunwald E, et al, for the ENGAGE AF-TIMI 48 Investigators. EdoXaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2014.
5.
5. Heidbuchel H, Verhamme P, Alings M, et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-2106.
6.
6. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban compared with warfarin in patients with atrial fibrillation and valvular heart disease: Findings from the ARISTOTLE trial. Circulation 2015;132624-632.
7.
7. Ezekowitz MD, Parise H, Nagarakanti R, et al. Comparison of dabigatran versus warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial. J Am Coll Cardiol 2014;63(12,suppl):A325.
8.
8. reithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroXaban vs warfarin in patients with non-valvular atrial fibrillation but native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35:3377-3385.
9.
9. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507.
10.
10. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015. DOI:10.1056/NEJMoa502000.
11.
11. FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa. http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm
12.
12. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016. DOI:10.1093/eurheartj/ehw210.
13.
13. Connolly SJ, Milling TJ, Eikelboom JW, et al, for the ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016. DOI:10.1056/ NEJMoa1607887.

Tác giả

Hồ Huỳnh Quang Trí: Viện Tim TP. Hồ Chí Minh;
No translate

Files

Article Views562
Document Views1
Downloads12
Section CHUYÊN ĐỀ
Pages 22-27
Copyright Holder 2016 Tạp chí Tim mạch học Việt Nam